PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Clinical trials for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) trials appear
Sign up with your email to follow new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New injection shows promise for rare bleeding disorder
Disease control Recruiting nowThis study tests a new drug called STSA-1301 for people with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The trial includes healthy volunteers and ITP patients to check safety, how the drug works in the body, and whethe…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu BioJeTay Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 04:05 UTC
-
New drug aims to boost platelets in chronic ITP patients
Disease control Recruiting nowThis study tests an IV medicine called efgartigimod in adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. About 69 participants will receive either the drug or a placebo for up to 24 weeks, then all wi…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 26, 2026 04:00 UTC
-
New shot aims to boost platelets in rare bleeding disorder
Disease control Recruiting nowThis early study tests a new drug called PN20 in 12 adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. Participants receive one injection and are monitored for safety and platelet count changes. The go…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE1 • Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 03:58 UTC
-
New combo therapy aims to tame rare bleeding disorder
Disease control Recruiting nowThis study tests whether adding the drug ianalumab to a standard platelet-boosting therapy is safe and tolerable for adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. Participants must have tried 1 to 4 pr…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
New hope for ITP patients: IVIG trial aims to boost platelets
Disease control Recruiting nowThis study tests a medicine called human immunoglobulin (5% IVIG) in adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The treatment is given through a vein for 5 days. The main goal is to see if it can ra…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE3 • Sponsor: Grand Shuyang Life Sciences (Chengdu) Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
New combo therapy aims to boost platelets in Hard-to-Treat ITP
Disease control Recruiting nowThis study tests whether adding rituximab to the standard drug eltrombopag works better than eltrombopag alone for adults with immune thrombocytopenia (ITP) who have not responded to or relapsed after previous treatments. About 224 participants will receive either the combination…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New 'T cell Engager' drug tested for tough autoimmune cases
Disease control Recruiting nowThis early-phase study tests the safety of a new drug called CC312 in up to 18 adults with autoimmune diseases like lupus, arthritis, or scleroderma that haven't responded to standard treatments. CC312 works by directing the body's immune T cells to attack faulty B cells, similar…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: EARLY_PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New drug combo aims to boost platelet counts in ITP patients
Disease control Recruiting nowThis study tests whether adding orelabrutinib to high-dose dexamethasone works better than dexamethasone alone for adults newly diagnosed with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. About 86 participants will receive either …
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE3 • Sponsor: Shandong University • Aim: Disease control
Last updated May 13, 2026 16:01 UTC